Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis.

Author(s): Saralaya D, Peckham DG, Hulme B, Tobin CM, Denton M, Conway S, Etherington C

Affiliation(s): Regional Adult Cystic Fibrosis Unit, Seacroft Hospital, York Road, Leeds LS14 6UH, UK.

Publication date & source: 2004-02, J Antimicrob Chemother., 53(2):325-8. Epub 2004 Jan 16.

Publication type: Clinical Trial; Randomized Controlled Trial

OBJECTIVES: Linezolid is a new oxazolidinone antibiotic with efficacy against a broad range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). In this study, we have determined the serum and sputum linezolid concentrations in adults with cystic fibrosis (CF) following oral drug administration. METHODS: Eleven adult patients with CF were recruited. Subjects received 600 mg of linezolid orally every 12 h for a total of six doses. Serum and sputum levels were measured just before and at 2 h after the final dose of linezolid. A further serum level was measured at 4 h. RESULTS: Ten adult patients completed the study. Mean (s.d.) serum linezolid concentrations were 2.3 mg/L (1.5) at 12 h following the fifth dose. At 2 and 4 h following the sixth dose, concentrations were 13.5 (4.3) and 8.1 (3.3). Mean (s.d.) linezolid sputum concentrations were 3.6 (2.1) and 17.4 (7.2) mg/L at 0 and 2 h following drug administration. CONCLUSIONS: The oral administration of linezolid results in good sputum penetration in patients with CF. Mean levels exceed the required MIC for the treatment of MRSA for >80% of the dosing period for serum and the majority of the dosing period for sputum.